Search Results

BioMidwest

C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories

C2N Diagnostics, LLC, which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients.

June 27, 2024

·

4 min read

Drug Development

Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients

Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N’s efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease in the U.S.

March 5, 2024

·

3 min read

News

C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide

September 25, 2024

·

8 min read

Press Releases

C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease

October 1, 2024

·

4 min read

BioMidwest

On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach

C2N Diagnostics is marking World Alzheimer’s Day by highlighting the growing international availability of the PrecivityAD2 blood test, a clinical care assay that helps healthcare providers identify amyloid plaques in the brain, which are recognized as key indicators of Alzheimer’s disease.

September 21, 2023

·

5 min read

Press Releases

C2N Diagnostics Says FDA’s Approval of Donanemab Highlights Its Role in Helping to Determine Alzheimer’s Disease Pathology

July 2, 2024

·

4 min read

BioMidwest

C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology

C 2 N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology.

October 25, 2023

·

4 min read

BioMidwest

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

C2N Diagnostics, a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test, a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.

August 17, 2023

·

6 min read

BioMidwest

C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market

C₂N Diagnostics, LLC announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation Group Company and premier provider of clinical research to the biopharma industry throughout Japan.

April 26, 2024

·

6 min read

BioMidwest

Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease

Scientists, clinicians, and others taking part in the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference learned the latest insights about C2N Diagnostics, LLC’s Precivity™ line of blood tests to facilitate earlier and more accurate diagnosis of Alzheimer’s disease pathology by healthcare providers.

November 16, 2023

·

7 min read